<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207399</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00074361</org_study_id>
    <nct_id>NCT03207399</nct_id>
  </id_info>
  <brief_title>Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment</brief_title>
  <official_title>Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment: A Pilot Feasibility and Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether treatment with Epclusa
      (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C
      infection is feasible, safe and effective at curing HCV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">September 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response 12 weeks (SVR 12) in those treated with EPCLUSA.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sustained Virologic Response 12 weeks (SVR 12) in those treated with EPCLUSA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients that reported an adverse event resulting in discontinuation of EPCLUSA</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events resulting in discontinuation of EPCLUSA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients eligible for EPCLUSA treatment</measure>
    <time_frame>within 12 months of lung transplant</time_frame>
    <description>Eligibility for EPCLUSA treatment within 12 months of lung transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum HCV RNA levels</measure>
    <time_frame>4, 12, 24, 36, and 48 weeks after initiation of EPCLUSA</time_frame>
    <description>Serum HCV RNA levels at 4-, 12-, 24-, 36- and 48-weeks after initiation of EPCLUSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events requiring temporary interruption of EPCLUSA therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events requiring temporary interruption in EPCLUSA therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>90 days post-transplant</time_frame>
    <description>90-day post transplant patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>1 year post-tranplant</time_frame>
    <description>1 year post transplant patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>90 days post-transplant</time_frame>
    <description>90-day post transplant patient survival in recipients of HCV NAT positive donor organ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>1 year post transplant patient survival in recipients of HCV NAT positive donor organ</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>Epclusa</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>Patients will be treated with this drug for 12 weeks post lung transplant.</description>
    <arm_group_label>Epclusa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA &gt;= 10^3 IU/ml at screening

          -  Chronic HCV infection, defined as positive HCV antibody and/or HCV RNA more than 6
             months prior to screening

          -  HCV Genotype 1, 2, 3, 4, 5 or 6

          -  Otherwise eligible for lung transplant at study site

        Exclusion Criteria:

          -  Age &lt;18

          -  Treatment with any of the following agents:

               -  Amiodarone. Subjects previously treated with amiodarone must have stopped the
                  amiodarone at least 60 days prior to day 1 SOF/VEL

               -  Carbamazepine, phenytoin, phenobarbital, oxcarbazepine

               -  Rifabutin, rifampin or rifapentine

               -  HIV regimens containing tenofovir or tipranavir/ritonavir

               -  St John's wort

               -  PPIs, including: Omeprazole, pantoprazole, esomeprazole, lansoprazole,
                  dexlansoprazole, rabeprazole

               -  Modafinil

          -  Have any serious or active medical or psychiatric illness which, in the opinion of the
             investigator, would interfere with subject treatment, assessment or compliance

          -  Hepatitis B surface antigen positive

          -  History of hepatic encephalopathy or variceal hemorrhage

          -  Abnormal hematological and biochemical parameters, including:

               -  Hemoglobin &lt;8g/dL

               -  Platelets &lt;= 50,000/mm^3

               -  ALT (alanine aminotransferase), AST (aspartase aminotransferase) or alkaline
                  phosphatase &gt;=10 times ULN

               -  Total bilirubin &gt;3mg/dL

               -  Severe renal impairment, ie creatinine clearance (CrCl) &lt;30mL/min

          -  Pregnant women or women planning to become pregnant

          -  Women or are breastfeeding

          -  Active or recent history (&lt;=1 year) of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Heath</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noely M Martinez Overby</last_name>
    <phone>919-681-3791</phone>
    <email>noely.martinez-overby@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather M Kuehn</last_name>
    <phone>919-479-0719</phone>
    <email>heather.kuehn@duk.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noely M Martinez Overby</last_name>
      <phone>919-681-3791</phone>
      <email>noely.martinez-overby@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Alice Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

